Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2007.14.7116 on March 3 2008

Journal of Clinical Oncology, Vol 26, No 10 (April 1), 2008: pp. 1626-1634
© 2008 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Amado, R. G.
Right arrow Articles by Chang, D. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amado, R. G.
Right arrow Articles by Chang, D. D.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Medline Plus Health Information
*Cancer Chemotherapy
*Colorectal Cancer
*Genetics Home Reference
Related Articles
Right arrowRelated Editorial
Right arrowRelated Correspondence
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Rafael G. Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J. Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky, Scott D. Patterson, David D. Chang

From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca’ Granda, Milan, Italy

Corresponding author: Rafael G. Amado, MD, Amgen, Inc, One Amgen Center Dr, MS 38-2-B, Thousand Oaks, CA 91320-1799; e-mail: ramado{at}amgen.com

Purpose Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials.

Patients and Methods KRAS mutations were detected using polymerase chain reaction on DNA from tumor sections collected in a phase III mCRC trial comparing panitumumab monotherapy to best supportive care (BSC). We tested whether the effect of panitumumab on progression-free survival (PFS) differed by KRAS status.

Results KRAS status was ascertained in 427 (92%) of 463 patients (208 panitumumab, 219 BSC). KRAS mutations were found in 43% of patients. The treatment effect on PFS in the wild-type (WT) KRAS group (hazard ratio [HR], 0.45; 95% CI: 0.34 to 0.59) was significantly greater (P < .0001) than in the mutant group (HR, 0.99; 95% CI, 0.73 to 1.36). Median PFS in the WT KRAS group was 12.3 weeks for panitumumab and 7.3 weeks for BSC. Response rates to panitumumab were 17% and 0%, for the WT and mutant groups, respectively. WT KRAS patients had longer overall survival (HR, 0.67; 95% CI, 0.55 to 0.82; treatment arms combined). Consistent with longer exposure, more grade III treatment-related toxicities occurred in the WT KRAS group. No significant differences in toxicity were observed between the WT KRAS group and the overall population.

Conclusion Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors. KRAS status should be considered in selecting patients with mCRC as candidates for panitumumab monotherapy.

published online ahead of print at www.jco.orgon March 3, 2008.

Funded by Amgen Inc, Thousand Oaks, CA.

Presented in part in oral format at the 14th European Cancer Conference, Barcelona, Spain, September 23-27, 2007; and the American Society of Clinical Oncology Gastrointestinal Cancer Symosium, Orlando, FL, January 25-27, 2008.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Editorial

  • Determinants of RASistance to Anti–Epidermal Growth Factor Receptor Agents
    José Baselga and Neal Rosen
    JCO 2008 26: 1582-1584 [Full Text]

Related Correspondence

  • Defining Best Supportive Care
    S. Yousuf Zafar, David Currow, and Amy P. Abernethy
    JCO 2008 26: 5139-5140 [Full Text]


This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
E. E. Mancl, J. M. Kolesar, and L. C. Vermeulen
Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors
Am. J. Health Syst. Pharm., December 1, 2009; 66(23): 2105 - 2112.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
N. I. Cherny, A. P. Abernethy, F. Strasser, R. Sapir, D. Currow, and S. Y. Zafar
Improving the Methodologic and Ethical Validity of Best Supportive Care Studies in Oncology: Lessons From a Systematic Review
J. Clin. Oncol., November 10, 2009; 27(32): 5476 - 5486.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
R. M. Simon, S. Paik, and D. F. Hayes
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
J Natl Cancer Inst, November 4, 2009; 101(21): 1446 - 1452.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
S. E. Taube, G. M. Clark, J. E. Dancey, L. M. McShane, C. C. Sigman, and S. I. Gutman
A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment
J Natl Cancer Inst, November 4, 2009; 101(21): 1453 - 1463.
[Abstract] [Full Text] [PDF]


Home page
Therapeutic Advances in Medical OncologyHome page
F. Loupakis, C. Cremolini, G. Fontanini, I. Stasi, L. Salvatore, and A. Falcone
Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer
Therapeutic Advances in Medical Oncology, November 1, 2009; 1(3): 167 - 181.
[Abstract] [PDF]


Home page
J. Mol. Diagn.Home page
C. Ausch, V. Buxhofer-Ausch, C. Oberkanins, B. Holzer, M. Minai-Pour, S. Jahn, N. Dandachi, R. Zeillinger, and G. Kriegshauser
Sensitive Detection of KRAS Mutations in Archived Formalin-Fixed Paraffin-Embedded Tissue Using Mutant-Enriched PCR and Reverse-Hybridization
J. Mol. Diagn., November 1, 2009; 11(6): 508 - 513.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
V. Whitehall, K. Tran, A. Umapathy, F. Grieu, C. Hewitt, T.-J. Evans, T. Ismail, W. Q. Li, P. Collins, P. Ravetto, et al.
A Multicenter Blinded Study to Evaluate KRAS Mutation Testing Methodologies in the Clinical Setting
J. Mol. Diagn., November 1, 2009; 11(6): 543 - 552.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer
J Natl Cancer Inst, October 7, 2009; 101(19): 1308 - 1324.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
E S K Ma, C L P Wong, F B F Law, W-K Chan, and D Siu
Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis
J. Clin. Pathol., October 1, 2009; 62(10): 886 - 891.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
M. Holdhoff, K. Schmidt, R. Donehower, and L. A. Diaz Jr
Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations
J Natl Cancer Inst, September 16, 2009; 101(18): 1284 - 1285.
[Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
N. Mittmann, H.-J. Au, D. Tu, C. J. O'Callaghan, P. K. Isogai, C. S. Karapetis, J. R. Zalcberg, W. K. Evans, M. J. Moore, J. Siddiqui, et al.
Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial
J Natl Cancer Inst, September 2, 2009; 101(17): 1182 - 1192.
[Abstract] [Full Text] [PDF]


Home page
Therapeutic Advances in Medical OncologyHome page
A. Grothey
Review: Medical treatment of advanced colorectal cancer in 2009
Therapeutic Advances in Medical Oncology, September 1, 2009; 1(2): 55 - 68.
[Abstract] [PDF]


Home page
JCOHome page
S. J. Mandrekar and D. J. Sargent
Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
J. Clin. Oncol., August 20, 2009; 27(24): 4027 - 4034.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
H. Piessevaux, M. Buyse, W. De Roock, H. Prenen, M. Schlichting, E. Van Cutsem, and S. Tejpar
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)
Ann. Onc., August 1, 2009; 20(8): 1375 - 1382.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
R. PALMIROTTA, A. SAVONAROLA, V. FORMICA, G. LUDOVICI, G. DEL MONTE, M. ROSELLI, and F. GUADAGNI
A Novel K-ras Mutation in Colorectal Cancer. A Case Report and Literature Review
Anticancer Res, August 1, 2009; 29(8): 3369 - 3374.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
H. Spiro, F. Roila, M. C. Garassino, E. Ballatori, E. Bria, F. Cuppone, M. Di Maio, S. Garattini, V. Torri, I. Floriani, et al.
Cetuximab for metastatic colorectal cancer.
N. Engl. J. Med., July 2, 2009; 361(1): 95 - 96.
[Full Text] [PDF]


Home page
Anticancer ResHome page
M. PESEK, L. BENESOVA, B. BELSANOVA, P. MUKENSNABL, F. BRUHA, and M. MINARIK
Dominance of EGFR and Insignificant KRAS Mutations in Prediction of Tyrosine-kinase Therapy for NSCLC Patients Stratified by Tumor Subtype and Smoking Status
Anticancer Res, July 1, 2009; 29(7): 2767 - 2773.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Tripathy
Are We Hitting the Right Combination for Hormonally Sensitive Breast Cancer?
J. Clin. Oncol., June 1, 2009; 27(16): 2580 - 2582.
[Full Text] [PDF]


Home page
JCOHome page
F. Loupakis, L. Pollina, I. Stasi, A. Ruzzo, M. Scartozzi, D. Santini, G. Masi, F. Graziano, C. Cremolini, E. Rulli, et al.
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
J. Clin. Oncol., June 1, 2009; 27(16): 2622 - 2629.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
B. Nordlinger, E. Van Cutsem, T. Gruenberger, B. Glimelius, G. Poston, P. Rougier, A. Sobrero, M. Ychou, and on behalf of the European Colorectal Metastases Tr
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel
Ann. Onc., June 1, 2009; 20(6): 985 - 992.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. J. Freeman, T. Bush, S. Ogbagabriel, B. Belmontes, T. Juan, C. Plewa, G. Van, C. Johnson, and R. Radinsky
Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor
Mol. Cancer Ther., June 1, 2009; 8(6): 1536 - 1546.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. M. Hoskins and H. L. McLeod
UGT1A and Irinotecan Toxicity: Keeping It in the Family
J. Clin. Oncol., May 20, 2009; 27(15): 2419 - 2421.
[Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
K. Muro, T. Yoshino, T. Doi, K. Shirao, H. Takiuchi, Y. Hamamoto, H. Watanabe, B.-B. Yang, and D. Asahi
A Phase 2 Clinical Trial of Panitumumab Monotherapy in Japanese Patients with Metastatic Colorectal Cancer
Jpn. J. Clin. Oncol., May 1, 2009; 39(5): 321 - 326.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
K. -L. Garm Spindler, N. Pallisgaard, A. A. Rasmussen, J. Lindebjerg, R. F. Andersen, D. Cruger, and A. Jakobsen
The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer
Ann. Onc., May 1, 2009; 20(5): 879 - 884.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Prenen, J. De Schutter, B. Jacobs, W. De Roock, B. Biesmans, B. Claes, D. Lambrechts, E. Van Cutsem, and S. Tejpar
PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
Clin. Cancer Res., May 1, 2009; 15(9): 3184 - 3188.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
B. J. Krause, K. Herrmann, H. Wieder, and C. M. zum Buschenfelde
18F-FDG PET and 18F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 89S - 96S.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
C.-H. Kohne and H.-J. Lenz
Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer
Oncologist, May 1, 2009; 14(5): 478 - 488.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
E. Van Cutsem, J. Oliveira, and On behalf of the ESMO Guidelines Working Group
Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc., May 1, 2009; 20(suppl_4): iv61 - iv63.
[Full Text] [PDF]


Home page
JCOHome page
C. J. Allegra, J. M. Jessup, M. R. Somerfield, S. R. Hamilton, E. H. Hammond, D. F. Hayes, P. K. McAllister, R. F. Morton, and R. L. Schilsky
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
J. Clin. Oncol., April 20, 2009; 27(12): 2091 - 2096.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. Vilar, B. Mukherjee, R. Kuick, L. Raskin, D. E. Misek, J. M.G. Taylor, T. J. Giordano, S. M. Hanash, E. R. Fearon, G. Rennert, et al.
Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway
Clin. Cancer Res., April 15, 2009; 15(8): 2829 - 2839.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H.-J. Au, C. S. Karapetis, C. J. O'Callaghan, D. Tu, M. J. Moore, J. R. Zalcberg, H. Kennecke, J. D. Shapiro, S. Koski, N. Pavlakis, et al.
Health-Related Quality of Life in Patients With Advanced Colorectal Cancer Treated With Cetuximab: Overall and KRAS-Specific Results of the NCIC CTG and AGITG CO.17 Trial
J. Clin. Oncol., April 10, 2009; 27(11): 1822 - 1828.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
E. Van Cutsem, C.-H. Kohne, E. Hitre, J. Zaluski, C.-R. Chang Chien, A. Makhson, G. D'Haens, T. Pinter, R. Lim, G. Bodoky, et al.
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
N. Engl. J. Med., April 2, 2009; 360(14): 1408 - 1417.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Staal, M. J. O'Connell, and C. J. Allegra
The Marriage of Growth Factor Inhibitors and Chemotherapy: Bliss or Bust?
J. Clin. Oncol., April 1, 2009; 27(10): 1545 - 1548.
[Full Text] [PDF]


Home page
AM J HOSP PALLIAT CAREHome page
R. L. Barros Costa
Review Article: Targeted Therapy: Comprehensive Review
American Journal of Hospice and Palliative Medicine, April 1, 2009; 26(2): 137 - 146.
[Abstract] [PDF]


Home page
Clin. Cancer Res.Home page
N. Dhani, D. Tu, D. J. Sargent, L. Seymour, and M. J. Moore
Alternate Endpoints for Screening Phase II Studies
Clin. Cancer Res., March 15, 2009; 15(6): 1873 - 1882.
[Abstract] [Full Text] [PDF]


Home page
J Oncol PractHome page
R. F. Morton and E. H. Hammond
ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab--Clinical Implications in Colorectal Cancer
J. Oncol. Pract, March 1, 2009; 5(2): 71 - 72.
[Full Text] [PDF]


Home page
J Oncol PractHome page
C. Stokoe
Adapting Practice in the Face of New Data
J. Oncol. Pract, March 1, 2009; 5(2): 83 - 85.
[Full Text] [PDF]


Home page
JCOHome page
A. Jimeno, W. A. Messersmith, F. R. Hirsch, W. A. Franklin, and S. G. Eckhardt
KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
J. Clin. Oncol., March 1, 2009; 27(7): 1130 - 1136.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
M. Pichler, M. Balic, E. Stadelmeyer, C. Ausch, M. Wild, C. Guelly, T. Bauernhofer, H. Samonigg, G. Hoefler, and N. Dandachi
Evaluation of High-Resolution Melting Analysis as a Diagnostic Tool to Detect the BRAF V600E Mutation in Colorectal Tumors
J. Mol. Diagn., March 1, 2009; 11(2): 140 - 147.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Sartore-Bianchi, M. Martini, F. Molinari, S. Veronese, M. Nichelatti, S. Artale, F. Di Nicolantonio, P. Saletti, S. De Dosso, L. Mazzucchelli, et al.
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Cancer Res., March 1, 2009; 69(5): 1851 - 1857.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. M. Schittenhelm, C. Kollmannsberger, K. Oechsle, A. Harlow, J. Morich, F. Honecker, R. Kurek, S. Storkel, L. Kanz, C. L. Corless, et al.
Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer
Mol. Cancer Ther., March 1, 2009; 8(3): 481 - 489.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. C. Stites and K. S. Ravichandran
A Systems Perspective of Ras Signaling in Cancer
Clin. Cancer Res., March 1, 2009; 15(5): 1510 - 1513.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
A. Marchetti, G. Gasparini, M. Albitar, C. Yeh, W. Ma, W. De Roock, D. Lambrechts, S. Tejpar, T. Winder, W. Scheithauer, et al.
K-ras Mutations and Cetuximab in Colorectal Cancer
N. Engl. J. Med., February 19, 2009; 360(8): 833 - 836.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Laurent-Puig, A. Lievre, and H. Blons
Mutations and Response to Epidermal Growth Factor Receptor Inhibitors
Clin. Cancer Res., February 15, 2009; 15(4): 1133 - 1139.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. R. Hecht, E. Mitchell, T. Chidiac, C. Scroggin, C. Hagenstad, D. Spigel, J. Marshall, A. Cohn, D. McCollum, P. Stella, et al.
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Clin. Oncol., February 10, 2009; 27(5): 672 - 680.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. Bokemeyer, I. Bondarenko, A. Makhson, J. T. Hartmann, J. Aparicio, F. de Braud, S. Donea, H. Ludwig, G. Schuch, C. Stroh, et al.
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
J. Clin. Oncol., February 10, 2009; 27(5): 663 - 671.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Garfield
Other Problems With Phase III Best Supportive Care Studies
J. Clin. Oncol., February 10, 2009; 27(5): 829 - 829.
[Full Text] [PDF]


Home page
NEJMHome page
R. J. Mayer
Targeted Therapy for Advanced Colorectal Cancer -- More Is Not Always Better
N. Engl. J. Med., February 5, 2009; 360(6): 623 - 625.
[Full Text] [PDF]


Home page
Ann OncolHome page
M. A. Pantaleo, M. Nannini, A. Maleddu, S. Fanti, C. Nanni, S. Boschi, F. Lodi, G. Nicoletti, L. Landuzzi, P. L. Lollini, et al.
Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer
Ann. Onc., February 1, 2009; 20(2): 213 - 226.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Velho, C. Oliveira, and R. Seruca
KRAS Mutations and Anti-Epidermal Growth Factor Receptor Therapy in Colorectal Cancer With Lymph Node Metastases
J. Clin. Oncol., January 1, 2009; 27(1): 158 - 159.
[Full Text] [PDF]


Home page
Ann OncolHome page
F. Perrone, A. Lampis, M. Orsenigo, M. Di Bartolomeo, A. Gevorgyan, M. Losa, M. Frattini, C. Riva, S. Andreola, E. Bajetta, et al.
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
Ann. Onc., January 1, 2009; 20(1): 84 - 90.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. Peeters, T. Price, and J.-L. Van Laethem
Anti-Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?
Oncologist, January 1, 2009; 14(1): 29 - 39.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
H. I. Hurwitz, J. Yi, W. Ince, W. F. Novotny, and O. Rosen
The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
Oncologist, January 1, 2009; 14(1): 22 - 28.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. Di Nicolantonio, M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti, S. De Dosso, L. Mazzucchelli, M. Frattini, S. Siena, et al.
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
J. Clin. Oncol., December 10, 2008; 26(35): 5705 - 5712.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. Wong and D. Cunningham
Using Predictive Biomarkers to Select Patients With Advanced Colorectal Cancer for Treatment With Epidermal Growth Factor Receptor Antibodies
J. Clin. Oncol., December 10, 2008; 26(35): 5668 - 5670.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clin. Chem., December 1, 2008; 54(12): e11 - e79.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
G. Milano, M.-C. Etienne-Grimaldi, L. Dahan, M. Francoual, J.-P. Spano, D. Benchimol, M. Chazal, C. Letoublon, T. Andre, F.-N. Gilly, et al.
Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer
Ann. Onc., December 1, 2008; 19(12): 2033 - 2038.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
D. Santini, F. Loupakis, B. Vincenzi, I. Floriani, I. Stasi, E. Canestrari, E. Rulli, P. E. Maltese, F. Andreoni, G. Masi, et al.
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
Oncologist, December 1, 2008; 13(12): 1270 - 1275.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. M. Ellis and D. G. Haller
Bevacizumab Beyond Progression: Does This Make Sense?
J. Clin. Oncol., November 20, 2008; 26(33): 5313 - 5315.
[Full Text] [PDF]


Home page
JCOHome page
S. Y. Zafar, D. Currow, and A. P. Abernethy
Defining Best Supportive Care
J. Clin. Oncol., November 1, 2008; 26(31): 5139 - 5140.
[Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
G. J. Riely and M. Ladanyi
KRAS Mutations: An Old Oncogene Becomes a New Predictive Biomarker
J. Mol. Diagn., November 1, 2008; 10(6): 493 - 495.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. A. Morgan, L. A. Parsels, J. Maybaum, and T. S. Lawrence
Improving Gemcitabine-Mediated Radiosensitization Using Molecularly Targeted Therapy: A Review
Clin. Cancer Res., November 1, 2008; 14(21): 6744 - 6750.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. J. Duffy and J. Crown
A Personalized Approach to Cancer Treatment: How Biomarkers Can Help
Clin. Chem., November 1, 2008; 54(11): 1770 - 1779.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
C. S. Karapetis, S. Khambata-Ford, D. J. Jonker, C. J. O'Callaghan, D. Tu, N. C. Tebbutt, R. J. Simes, H. Chalchal, J. D. Shapiro, S. Robitaille, et al.
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
N. Engl. J. Med., October 23, 2008; 359(17): 1757 - 1765.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
W. A. Messersmith and D. J. Ahnen
Targeting EGFR in Colorectal Cancer
N. Engl. J. Med., October 23, 2008; 359(17): 1834 - 1836.
[Full Text] [PDF]


Home page
JCOHome page
A. Grothey and D. J. Sargent
New Lessons From "Old" Chemotherapy in Colorectal Cancer
J. Clin. Oncol., October 1, 2008; 26(28): 4532 - 4534.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Simon
The Use of Genomics in Clinical Trial Design
Clin. Cancer Res., October 1, 2008; 14(19): 5984 - 5993.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. R. Alberts and L. D. Wagman
Chemotherapy for Colorectal Cancer Liver Metastases
Oncologist, October 1, 2008; 13(10): 1063 - 1073.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Artale, A. Sartore-Bianchi, S. M. Veronese, V. Gambi, C. S. Sarnataro, M. Gambacorta, C. Lauricella, and S. Siena
Mutations of KRAS and BRAF in Primary and Matched Metastatic Sites of Colorectal Cancer
J. Clin. Oncol., September 1, 2008; 26(25): 4217 - 4219.
[Full Text] [PDF]


Home page
Therapeutic Advances in GastroenterologyHome page
J. M. Carethers
Review: Systemic treatment of advanced colorectal cancer: Tailoring therapy to the tumor
Therapeutic Advances in Gastroenterology, July 1, 2008; 1(1): 33 - 42.
[Abstract] [PDF]


Home page
JCOHome page
M. S. Braun, S. D. Richman, P. Quirke, C. Daly, J. W. Adlard, F. Elliott, J. H. Barrett, P. Selby, A. M. Meade, R. J. Stephens, et al.
Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial
J. Clin. Oncol., June 1, 2008; 26(16): 2690 - 2698.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Lievre and P. Laurent-Puig
In Reply
J. Clin. Oncol., May 20, 2008; 26(15): 2601 - 2602.
[Full Text] [PDF]


Home page
JCOHome page
J. Baselga and N. Rosen
Determinants of RASistance to Anti-Epidermal Growth Factor Receptor Agents
J. Clin. Oncol., April 1, 2008; 26(10): 1582 - 1584.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online